Spyre Therapeutics
Stock Forecast, Prediction & Price Target
Spyre Therapeutics (SYRE) stock Price Target by analysts
$53.67
Potential upside: 233.12%
Spyre Therapeutics price prediction
What is Spyre Therapeutics stock analysts` prediction?
Spyre Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Spyre Therapeutics in the last 3 months, the avarage price target is $53.67, with a high forecast of $NaN. The average price target represents a 233.12% change from the last price of $16.11.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Spyre Therapeutics stock Price Target by analysts
Full breakdown of analysts given Spyre Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Alex Thompson Stifel Nicolaus | 0% 0/1 | 10 months ago | $71 340.72% upside | $35.52 | StreetInsider | Previous targets (0) |
Colleen Kusy Robert W. Baird | 0% 0/1 | 11 months ago | $50 210.36% upside | $32.37 | StreetInsider | Previous targets (0) |
Yanan Zhu Wells Fargo | 0% 0/1 | 11 months ago | $40 148.29% upside | $30.66 | StreetInsider | Previous targets (0) |
Julian Harrison BTIG | 0% 0/1 | over 1 year ago | $40 148.29% upside | $35.19 | TheFly | Previous targets (0) |
Spyre Therapeutics Financial Estimates
Spyre Therapeutics Revenue Estimates
Spyre Therapeutics EBITDA Estimates
Spyre Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $18.73M N/A | $2.32M -87.57% | $886K -61.95% | Avg: $4.42M Low: $4.42M High: $4.42M avg. 399.83% | Avg: $200K Low: $200K High: $200K avg. -95.48% | Avg: $136.21K Low: $136.21K High: $136.21K avg. -31.89% | Avg: $85.29K Low: $85.29K High: $85.29K avg. -37.38% |
Net Income
% change YoY
| $-65.80M N/A | $-83.81M -27.37% | $-338.79M -304.21% | Avg: $-180.02M Low: $-36.89M High: $-9.65M avg. 46.86% | Avg: $-201.95M Low: $-43.31M High: $-9.58M avg. -12.18% | Avg: $-40.55M Low: $-40.55M High: $-40.55M avg. 79.91% | Avg: $-37.72M Low: $-37.72M High: $-37.72M avg. 6.97% |
EBITDA
% change YoY
| $-64.07M N/A | $-83.21M -29.87% | $-127.82M -53.60% | Avg: $885.71K Low: $885.71K High: $885.71K avg. 100.69% | Avg: $39.99K Low: $39.99K High: $39.99K avg. -95.48% | Avg: $27.24K Low: $27.24K High: $27.24K avg. -31.89% | Avg: $17.05K Low: $17.05K High: $17.05K avg. -37.38% |
EPS
% change YoY
| -$25.02 N/A | -$24.86 0.63% | -$49.12 -97.58% | Avg: -$3.58 Low: -$5.35 High: -$1.4 avg. 92.71% | Avg: -$4.23 Low: -$6.28 High: -$1.39 avg. -18.15% | Avg: -$5.88 Low: -$5.88 High: -$5.88 avg. -39.00% | Avg: -$5.47 Low: -$5.47 High: -$5.47 avg. 6.97% |
Operating Expenses
% change YoY
| $84.38M N/A | $87.11M 3.22% | $243.18M 179.17% | Avg: $53.84M Low: $53.84M High: $53.84M avg. -77.85% | Avg: $2.43M Low: $2.43M High: $2.43M avg. -95.48% | Avg: $1.65M Low: $1.65M High: $1.65M avg. -31.89% | Avg: $1.03M Low: $1.03M High: $1.03M avg. -37.38% |
FAQ
What is Spyre Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 30.39% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -36.89M, average is -180.02M and high is -9.65M.
What is Spyre Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 58.76% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $4.42M, average is $4.42M and high is $4.42M.
What is Spyre Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 10.63% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$5.35, average is -$3.58 and high is $-1.4.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Spyre Therapeutics stock. The most successful analyst is Alex Thompson.